Edwards Lifesciences
964 hedge funds and large institutions have $37.9B invested in Edwards Lifesciences in 2019 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 314 increasing their positions, 354 reducing their positions, and 69 closing their positions.
71% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 69
43% more funds holding in top 10
Funds holding in top 10: 21 → 30 (+9)
32% more call options, than puts
Call options by funds: $380M | Put options by funds: $289M
19% more capital invested
Capital invested by funds: $32B → $37.9B (+$5.92B)
5% more funds holding
Funds holding: 921 → 964 (+43)
0.57% less ownership
Funds ownership: 249.45% → 248.88% (-0.57%)
11% less repeat investments, than reductions
Existing positions increased: 314 | Existing positions reduced: 354
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$205M |
| 2 |
Millennium Management
New York
|
+$143M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$119M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$97M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$125M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$113M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$88.1M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$77.5M |
| 5 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$72.6M |
EW Hedge Fund Activity: Q3 2019 in Review
964 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2019, worth a combined $37.9B — up 19% from $32B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new EW positions and 69 closed out — a net gain of 49 holders — while 314 added to existing stakes and 354 trimmed.
The largest buyer was Capital International Investors, adding an estimated $205M. The largest seller was Capital Research Global Investors, cutting an estimated $125M.
- 964 institutional investors held Edwards Lifesciences (EW) as of Q3 2019, up from 921 in Q2 2019.
- Funds reported $37.9B of Edwards Lifesciences stock for Q3 2019, up 19% quarter-over-quarter.
- 118 funds opened new Edwards Lifesciences positions in Q3 2019 and 69 closed out, a net change of +49 holders.
- The largest Edwards Lifesciences buyer in Q3 2019 was Capital International Investors, an estimated $205M added.
- The largest Edwards Lifesciences seller in Q3 2019 was Capital Research Global Investors, an estimated $125M sold.
Based on aggregated 13F filings for Q3 2019.